2nd Fl
Palo Alto, CA 94304
Phone: (650) 721-2250
Fax: (650) 721-3822
Fax: (650) 721-3822
The latest information about the 2019 Novel Coronavirus, including vaccine clinics for children ages 6 months and older.
La información más reciente sobre el nuevo Coronavirus de 2019, incluidas las clínicas de vacunación para niños de 6 meses en adelante.
Amrita Narang, MD
- Clinical Assistant Professor
- “I partner with the whole family to help a child grow and thrive.”
As a pediatric gastroenterologist who specializes in transplant hepatology, I provide care for children with liver diseases and those needing liver transplant. My greatest intent is to help children reach their full potential through evidence-based care in collaboration with the family. My focus is always on the child, not the disease. As a clinical researcher, I strive to improve the quality of life for children with gastroenterology and hepatology conditions.
Specialties
Gastroenterology
Work and Education
Professional Education
New York Medical College Registrar, Valhalla, NY, 5/31/2012
Residency
Baylor College of Medicine Pediatric Residency, Houston, TX, 06/30/2015
Fellowship
Children's Hospital Los Angeles Pediatric Gastroenterology, Los Angeles, CA, 6/30/2018
Children's Hospital Los Angeles Pediatric Transplant Hepatology, Los Angeles, CA, 8/23/2019
Board Certifications
Pediatrics, American Board of Pediatrics
Transplant Hepatology, American Board of Pediatrics
Conditions Treated
Intestinal Transplant
Liver Disease
Liver Transplant
All Publications
Health Care Transition for Adolescents and Young Adults with Pediatric-Onset Liver Disease and Transplantation: A Position Paper by the North American Society of Pediatric Gastroenterology, Hepatology, and Nutrition. Journal of pediatric gastroenterology and nutrition 2022
Abstract
Advances in medical therapies and liver transplantation have resulted in a greater number of pediatric patients reaching young adulthood. However, there is an increased risk for medical complications and morbidity surrounding transfer from pediatric to adult hepatology and transplant services. Health care transition (HCT) is the process of moving from a child/family-centered model of care to an adult or patient-centered model of health care. Successful HCT requires a partnership between pediatric and adult providers across all disciplines resulting in a transition process that does not end at the time of transfer but continues throughout early adulthood. Joint consensus guidelines in collaboration with the American Society of Transplantation (AST) are presented to facilitate adoption of a structured, multidisciplinary approach to transition planning utilizing The Six Core Elements of Health Care TransitionTM for use by both pediatric and adult specialists. This paper provides guidance and seeks support for the implementation of a HCT program which spans across both pediatric and adult hepatology and transplant centers.
View details for DOI 10.1097/MPG.0000000000003560
View details for PubMedID 35830731
Profound neonatal lactic acidosis and renal tubulopathy in a patient with glycogen storage disease type IXa2 secondary to a de novo pathogenic variant in PHKA2 MOLECULAR GENETICS AND METABOLISM REPORTS 2021; 27
View details for DOI 10.1016/j.ymgmr.2021.100765
View details for Web of Science ID 000656785700011
Severe Late-Onset Acute Cellular Rejection in a Pediatric Patient With Isolated Small Intestinal Transplant Rescued With Aggressive Immunosuppressive Approach: A Case Report. Transplantation proceedings 2019; 51 (9): 3181-3185
Abstract
Small intestinal transplantation is performed for patients with intestinal failure who failed other surgical and medical treatment. It carries notable risks, including, but not limited to, acute and chronic cellular rejection and graft malfunction. Late severe acute intestinal allograft rejection is associated with increased risk of morbidity and mortality and, in the majority of cases, ends with total enterectomy. It usually results from subtherapeutic immunosuppression or nonadherence to medical treatment. We present the case of a 20-year-old patient who underwent isolated small bowel transplant for total intestinal Hirschsprung disease at age 7. Due to medication nonadherence, she developed severe late-onset acute cellular rejection manifested by high, bloody ostomy output and weight loss. Ileoscopy showed complete loss of normal intestinal anatomic landmarks and ulcerated mucosa. Graft biopsies showed ulceration and granulation tissue with severe architectural distortion consistent with severe intestinal graft rejection. She initially received intravenous corticosteroids and increased tacrolimus dose without significant improvement. Her immunosuppression was escalated to include infliximab and finally antithymocyte globulin. Graft enterectomy was considered repeatedly; however, clinical improvement was noted eventually with evidence of histologic improvement and salvage of the graft. The aggressive antirejection treatment was complicated by development of post-transplant lymphoproliferative disorder that resolved with reducing immunosuppression. Her graft function is currently maintained on tacrolimus, oral prednisone, and a periodic infliximab infusion. We conclude that a prompt and aggressive immunosuppressive approach significantly increases the chance of rescuing small bowel transplant rejection.
View details for DOI 10.1016/j.transproceed.2019.08.012
View details for PubMedID 31711586
A 10-Year united network for organ sharing review of mortality and risk factors in young children awaiting liver transplantation. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2016; 22 (11): 1584-1592
Abstract
Young children<2 years of age with chronic end-stage liver disease (YC2) are a uniquely vulnerable group listed for liver transplantation, characterized by a predominance of biliary atresia (BA). To investigate wait-list mortality, associated risk factors, and outcomes of YC2, we evaluated United Network for Organ Sharing registry data from April 2003 to March 2013 for YC2 listed for deceased donor transplant (BA=994; other chronic liver disease [CLD]=221). Overall, wait-list mortality among YC2 was 12.4% and posttransplant mortality was 8%, accounting for an overall postlisting mortality of 19.6%. YC2 demonstrated 12.2%, 18.7%, and 20.6% wait-list mortality by 90, 180, and 270 days, respectively. YC2 with CLD demonstrated significantly higher wait-list mortality compared with BA among YC2 (23.9% versus 9.8%; P<0.05). Multivariate analyses revealed that listing Pediatric End-Stage Liver Disease [PELD]>21 (hazard ratio [HR], 3.2; 95% confidence interval [CI], 1.6-6.5), lack of exception (HR, 5.8; 95% CI, 2.8-11.8), listing height<60.6cm (HR, 2.1; 95% CI, 1.4-3.1), listing weight >10kg (HR, 3.8; 95% CI, 1.5-9.2), and initial creatinine>0.5 (HR, 6.8; 95% CI, 3.4-13.5) were independent risk factors for YC2 wait-list mortality (P<0.005 for all). Adjusting for all variables, the risk of death among CLD patients was 2 (95% CI, 1.3-3.1) times greater than patients with BA+surgery (presumed Kasai). Furthermore, the risk of death in BA without surgery was 1.9 (95% CI, 13.4) times greater than BA with presumed Kasai. Our data highlight unacceptably high wait-list and early post-liver transplant mortality in YC2 not predicted by PELD and suggest key risk factors deserving of further study in this age group. Liver Transplantation 22 1584-1592 2016 AASLD.
View details for DOI 10.1002/lt.24605
View details for PubMedID 27541809
View details for PubMedCentralID PMC5083224
Connect
- © 2023 Stanford MEDICINE Children's Health
